Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2024. Fourth Quarter Financial Highlights: Fourth quarter revenue increased 7% to $14 million Adjusted EBITDA fourth quarter income of $884,000 Fourth quarter gross margin on pharmacology services of 49% Fiscal Year 2024 Financial Highlights: Annual revenue of $50.2 million, a decrease of 7% year-over-year Fiscal Year 2024 adjusted EBITDA loss of $3.9 million Fiscal Year 2024 gross margin on pharmacology services of 42% Ronnie Morris, CEO of Champions, commented, "As we discussed over the year, we'd be facing hurdles during fiscal 2024 due to the challenging funding environment in the biotech sector and a range of spending patterns from our larger pharmaceutical companies, leading to a slowdown in sales growth and an increase in cancellations.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April 30, 2024, on Thursday, July 18, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
